\pagebreak

\begin{table*}[htb]
\caption{Literuature summary of known DPP4 substrates}
\label{DPP4-Sub}

\centering

\tiny
\setlength\tabcolsep{1.5pt}

\begin{tabular}{|l|l|l|l|c|c|l|c|l|}
    \hline
    \ Categories & Substrates & UniProt ID & N-terminal Seq & Size(aa) \textendash\, Start, End& \textit{In vivo} OR \textit{In vitro} & Biophysiological effects upon cleavage & Half-life (Average) & References \\
    \hline
    \multirow{19}{*}{Immune Response} & CXCL2 & P19875 & AP \textbar\; LATELRCQCL & 75 \textendash\, 35,107 & \textit{In vitro} & Increased hematopoietic activity & \textendash & \cite{10725737,  Ajami:2008oz} \\
    \hline
    & CXCL6 / GCP-2 & P80162 & GP \textbar\; VSAVLTELR & 77 \textendash\, 38,114 & \textit{In vitro} & Inactivation & \textendash & \cite{Proost:1998kl} \\
    \hline 
    & CXCL9 / MIG & Q07325 & TP \textbar\; VVRKGRCSCI & 105 \textendash\, 23,125 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR3 signaling & 24 mins & \cite{Lambeir:2001ab} \\
    \hline 
    & CXCL10 / IP10 & P02778 & VP \textbar\; LSRTVRCT & 73 \textendash\, 22,94 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR3 signaling & 4 mins & \cite{Lambeir:2001ab, 12173928} \\
    \hline
    & CXCL11 / IP-9 / I-TAC & O14625 & FP \textbar\; MFKRGRCL & 72 \textendash\, 22,94 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR3 signaling & 2 mins & \cite{Proost:1998kl, Lambeir:2001ab, Ludwig:2002aa} \\
    \hline 
    & CXCL12 / SDF1 & \multirow{2}{*}{P48061} & KP \textbar\; VSLSYRCP & 69 \textendash\, 22,88 & \multirow{2}{*}{\textit{In vitro}} & \multirow{2}{*}{Inactivation}; \multirow{2}{*}{Reduced chemotactic potential via CXCR4 signaling} & \multirow{2}{*}{\textless 1 mins} & \multirow{2}{*}{\cite{Proost:1998kl, Shioda:1998aa, Lambeir:2001ab}} \\
    & SDF1-\alpha / SDF1-\beta & & VS \textbar\; LSYRCP & 67 \textendash\, 24,88 & & & & \\ 
    \hline 
    & CCL3L1 / MIP  & \multirow{2}{*}{P16619} & AP \textbar\; LAADTPTAC & 70 \textendash\, 24,93 & \multirow{2}{*}{\textit{In vitro}} & \multirow{2}{*}{Inactivation; Increased chemotactic potential via CCR1 and CCR5 signaling} & \multirow{2}{*}{6000 mins} & \multirow{2}{*}{\cite{Proost:1998kl,Lambeir:2001ab}} \\
    & LD78\beta & & LA \textbar\; ADTPTAC & 68 \textendash\, 26,93 & & & & \\
    \hline 
    & CCL5 & \multirow{2}{*}{P13501} & SP \textbar\; YSSDTTPC & 67 \textendash\, 24,91  & \multirow{2}{*}{\textit{In vitro}} & \multirow{2}{*}{Altered receptor specificity; preferentially binds to CCR5 instead of CCR1} & \multirow{2}{*}{400 mins} & \multirow{2}{*}{\cite{Oravecz:1997aa, Lambeir:2001ab}} \\
    & RANTES & & YS \textbar\; SDTTPC & 65 \textendash\, 26,91 & & & & \\
    \hline 
    & CCL11 / Eotaxin & P51671 & GP \textbar\; ASVPTTCCF & 74 \textendash\, 24, 97 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CCR3 signaling & 30 mins & \cite{Lambeir:2001ab, Struyf:1999aa, Ajami:2008oz, 18606664} \\
    \hline 
    & CCL22 / MDC & O00626 & GP \textbar\; YGANMEDS & 69 \textendash\, 25,93 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CCR4 signaling & 1.6 \textbar\, 5.5 mins & \cite{Lambeir:2001ab} \\
    \hline 
    & \multirow{2}{*}{MIP1\alpha / LD78\alpha} &  \multirow{2}{*}{P10147} & AD \textbar\; TPTACCFSY & 68 \textendash\, 27,92 & \multirow{2}{*}{\textit{In vitro}} & \multirow{2}{*}{No reported effect} & \multirow{2}{*}{\textendash} & \multirow{2}{*}{\cite{Proost:1998kl}} \\
    & & & TP \textbar\; TACCFSY & 66 \textendash\, 29,92 & & & & \\
    \hline 
    & Erythropoiethin & P01588 & AP \textbar\; PRLICDSRVLE & 168 \textendash\, 28,193 & \textit{In vivo} & Inhibtion; reduced reticulate response & \textendash & \cite{23160239} \\
    \hline 
    & LECT-2 & O14960 & GP \textbar\; WANICAGKSSN & 135 \textendash\, 19,151 & \textit{In vitro} &  & \textendash &  \\
    \hline 
    & G-CSF & P09919 & AT \textbar\; PLGPASSLPQ & 180 \textendash\, 30,207 & \textit{In vivo} & Inactivation; reduced chemotaxis response & \textendash & \cite{23160239} \\
    \hline 
    & GM-CSF & P04141 & AP \textbar\; ARSPSPSTQP & 129 \textendash\, 18,144 & \textit{In vivo} & Inactivation & 480 mins & \cite{23160239, 23000011}} \\
    \hline
    \hline 
    
    \multirow{10}{*}{Neuropeptides} & PYY & P10082 & YP \textbar\; IKPEAPREDA & 38 \textendash\, 29,64 & \textit{In vivo} & Altered receptor specificity & 60 mins & \cite{Mentlein:1993aa, 12167864, 16802131, 20380653} \\
    \hline 
    & NPY & P01303 & YP \textbar\; SKPDNPGED & 38 \textendash\, 29,64 & \textit{In vitro} & Increase YR2/YSR receptor affinity & 6 mins & \cite{Mentlein:1993aa, Lambeir:2001ab, Frerker:2007rw} \\
    \hline 
    & Vasostatin-1 & \multirow{3}{*}{P10645} & \multirow{3}{*}{LP \textbar\; VNSPMNKGD} & 76 \textendash\, 19,94 & \multirow{3}{*}{\textit{In vitro}} & \multirow{3}{*}{\textendash} & \multirow{3}{*}{4 mins} & \multirow{3}{*}{\cite{12442257}} \\
    & Vasostatin-2 & & & 113 \textendash\, 19,131 & & & \\
    & Chromogranin-A & & & 439 \textendash\, 19,457 & & & \\
    \hline 
    & Substance P & P20366 & RP \textbar\; KPQQFFGLM & 11 \textendash\, 58,68 & \textit{In vitro} & Inactivation & 8 mins & \cite{12039843, Yazbeck:2009la, Mentlein:1993aa} \\
    \hline 
    & LVV-hemorphin-7 & \multirow{2}{*}{P68871} &  YP \textbar\; WTQRF & 7 \textendash\, 36,42 & \multirow{2}{*}{\textit{In vitro}} & \multirow{2}{*}{\textendash} & \multirow{2}{*}{\textendash} & \multirow{2}{*}{\textendash} \\
    & Spinorphin & & YP \textbar\; WT & 4 \textendash\, 39,42 & & & \\
    \hline 
    & PACAP 27 & \multirow{2}{|}{P18509} & \multirow{2}{|}{HS \textbar\; DGIFTDSYSR} & 27 \textendash\, 132,158 & \multirow{2}{|}{\textit{In vitro}} & \multirow{2}{|}{Inactivation} & \multirow{2}{|}{\textendash} & \multirow{2}{l|}{\cite{12690116, Lambeir:2001ab}} \\
    & PACAP 38 & & & 38 \textendash\, 132,169 & & & & \\
    \hline 
    \hline 
    
    \multirow{17}{*}{Digestive System} & Glucagon & \multirow{4}{*}{P01275} & HS \textbar\; QGTFTSDYSK & 29 \textendash\, 53,81 & \multirow{4}{*}{\textit{In vivo}} & \multirow{4}{*}{Inactivation} & \multirow{4}{*}{\textendash} & \multirow{4}{*}{\cite{Mentlein:1993aa, Hartmann:2000aa, 12690116, Mentlein_1999, Drucker:1997aa}} \\
    & GLP-1 & & HA \textbar\; EGTFTSDVSS & 30 \textendash\, 98,127 & & & & \\
    & GLP-2 & & HA \textbar\; DGSFSDEMNT & 33 \textendash\, 146,178 & & & & \\
    & Oxyntomodulin & & HS \textbar\, QGTFTSDYSK & 37 \textendash\, 53,89 & & & & \\
    \hline 
    & GIP & P09681 & YA \textbar\; EGTFISDYS & 42 \textendash\, 52,93 & \textit{In vivo} & Inactivation & & \cite{Mentlein:1993aa, 15491793} \\
    \hline 
    & PHM-27 & \multirow{3}{*}{P01282} & HA \textbar\, DGVFTSDFS & 27 \textendash\, 81,107 & \multirow{3}{*}{\textit{In vitro}} & \multirow{3}{*}{ \textendash} & \multirow{3}{*}{\textendash} & \multirow{3}{*}{\cite{15013843}} \\
    & PHV-42 & & HA \textbar\; DGVFTSDFS & 42 \textendash\, 81,122 & & & & \\
    & VIP & & HS \textbar\; DAVFTDNYT & 28 \textendash\,125,152 & & & & \\
    \hline 
    & \multirow{2}{*}{GRP-25} & \multirow{2}{*}{P07492} & VP \textbar\;LPAGGGTV & \multirow{2}{*}{\textit{In vitro}} & \multirow{2}{*}{Inactivation} & \multirow{2}{*}{\textendash} & \multirow{2}{*}{\textendash} & \multirow{2}{*}{\cite{Yazbeck2009, Sulda:2010ay}} \\
    & & LP \textbar\, AGGGTVLT & 25 \textendash\,26,50 & & & & \\
    \hline
    & Enterostatin & P01042 & AP \textbar\; GPR & 5 \textendash\, 18,22 & \textendash & \textendash &  \textendash &  \textendash \\
    \hline
    & Bradykinin & P01042 & RP \textbar\; PGFSPFR & 9 \textendash\, 381,389 & \textendash & \textendash & \textendash & \textendash \\
    \hline
    & Natriuretic peptide B & \multirow{3}{*}{P16860} & HP \textbar\; LGSPGSASD & 108 \textendash\, 27,134 & \multirow{3}{*}{\textendash} & \multirow{3}{*}{\textendash} & \multirow{3}{*}{\textendash} & \multirow{3}{*}{\textendash} \\
    & BNP-32 & & SP \textbar\; KMVQGSGC & 32 \textendash\, 103,134 & & & & \\
    & BNP & & SP \textbar\; KMVQGSGC & 30 \textendash\, 103,132 & & & & \\
    \hline
    & GHRF & \multirow{2}{*}{P01286} & PP \textbar\; PPLTLRMRR & 11 \textendash\, 21,31 & \multirow{2}{*}{\textit{In vivo}} & \multirow{2}{*}{Inactivation} & \multirow{2}{*}{\textendash} & \multirow{2}{*}{\cite{Frohman:1989aa, Yazbeck2009}} \\
    & Somatoliberin & & YA \textbar\; DAIF & 44 \textendash\, 32,75 & & & & \\
    \hline \hline
    
    Metabolism & IGF-1 & P05019 & GP \textbar\; ETLCGAELV & 70 \textendash\, 49,118 & \textendash & \textendash & \textendash & \textendash \\
    \hline \hline 
    
    \multirow{5}{*}{Small Molecules} & Morphiceptin & NA & YP \textbar\; FP & \textendash & \multirow{5}{*}{\textit{In vitro}} & \textendash & \textendash & \textendash \\
    & Endomorphin-1 & NA & YP \textbar\; WF & \textendash & & \textendash & \textendash & \textendash \\
    & Endomorphin-2 & NA & YP \textbar\; FF & \textendash & & \textendash & \textendash & \textendash \\
    & \beta -Casomorphin & NA & YP \textbar\; FVEPI & \textendash & & \textendash & \textendash & \textendash \\
    & Aprotinin & NA & RP \textbar\; DFC & \textendash & & \textendash & \textendash & \textendash \\
    \hline \hline 
\end{tabular}
\end{table*}

\pagebreak